Fennec Pharmaceuticals Inc. (TSE:FRX – Get Rating) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$7.77 and traded as high as C$8.59. Fennec Pharmaceuticals shares last traded at C$8.59, with a volume of 100 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Wedbush restated an “outperform” rating on shares of Fennec Pharmaceuticals in a research report on Thursday, May 12th.
Fennec Pharmaceuticals Stock Down 1.2 %
The business has a 50-day simple moving average of C$7.77 and a two-hundred day simple moving average of C$7.20. The stock has a market capitalization of C$223.68 million and a P/E ratio of -10.50. The company has a quick ratio of 8.55, a current ratio of 8.96 and a debt-to-equity ratio of 39.84.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
- Two High-Yield Deep-Values You Shouldn’t Ignore
- PayPal Continues To Struggle As Competition Increases
- Is Starbucks Shooting For The Moon?
- AutoNation Stock is Firing on All Pistons
- Caterpillar Falls To Strong Support Near Bottom Of Range
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.